Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China; Department of Obstetrics and Gynecology, Daxing District Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
Curr Probl Cancer. 2020 Apr;44(2):100514. doi: 10.1016/j.currproblcancer.2019.100514. Epub 2019 Nov 14.
Debates exist about the effects of peritoneal cytology and its treatment on the survival of early endometrial cancer. This study is to explore the prognostic role of peritoneal cytology and relevant therapy in patients with stage IA endometrial endometrioid carcinomas in a retrospective cohort study.
From June 1, 2010, to June 1, 2017, in a teaching hospital, all the cases of pathologically confirmed stage IA endometrioid endometrial cancer were reviewed. Patients were followed up to February 1, 2019. The survival outcomes were compared among patients with negative peritoneal cytology, positive peritoneal cytology and no peritoneal cytology outcomes.
In total, 1284 patients were included in the study, and 754 (58.7%) had peritoneal cytology evaluations with 22 (2.9%) of positive peritoneal cytology. After a median follow-up of 57.4 months, 1257 patients (97.9%) had definite survival outcomes. None of the patients with positive peritoneal cytology had recurrence or mortality. The appearance of positive peritoneal cytology had no impact on the disease-free, overall and cancer-specific overall survivals in univariate and multivariate analyses. No risk factors, including the adjuvant therapy, were found to be relevant with the appearance and survival in patients with positive peritoneal cytology.
In patients with stage IA endometrial endometrioid carcinoma, the prevalence of positive peritoneal cytology was very low without know risk factor. Positive peritoneal cytology did not influence the survival outcomes of whole population, and adjuvant therapy did not influence the survival outcomes of patients with positive peritoneal cytology in such population. Mini Abstract The appearance of positive peritoneal cytology in stage IA endometrial endometrioid carcinomas had no clinical significance and need no adjuvant therapy.
关于腹膜细胞学检查及其治疗对早期子宫内膜癌生存的影响存在争议。本研究旨在通过回顾性队列研究探讨腹膜细胞学检查及其相关治疗在 IA 期子宫内膜内膜样癌患者中的预后作用。
2010 年 6 月 1 日至 2017 年 6 月 1 日，在一所教学医院，对所有经病理证实为 IA 期子宫内膜内膜样癌的病例进行了回顾性分析。患者随访至 2019 年 2 月 1 日。比较腹膜细胞学阴性、阳性和无腹膜细胞学结果的患者的生存结局。
共纳入 1284 例患者，754 例（58.7%）行腹膜细胞学检查，其中 22 例（2.9%）为阳性。中位随访 57.4 个月后，1257 例（97.9%）患者有明确的生存结局。阳性腹膜细胞学患者无一例出现复发或死亡。单因素和多因素分析显示，阳性腹膜细胞学的出现对无病生存率、总生存率和癌症特异性总生存率均无影响。未发现包括辅助治疗在内的任何危险因素与阳性腹膜细胞学患者的出现和生存相关。
IA 期子宫内膜内膜样癌患者中，阳性腹膜细胞学的发生率非常低，且无明确的危险因素。阳性腹膜细胞学对全人群的生存结局无影响，辅助治疗对该人群中阳性腹膜细胞学患者的生存结局也无影响。
